Wave Life Sciences (WVE), a clinical-stage biotechnology company, on Thursday initiated the Phase 1 INLIGHT clinical trial for WVE-007, a novel, long-acting RNA-based therapeutic aimed at treating obesity. WVE-007 is a GalNAc-conjugated small interfering RNA or siRNA designed to target INHBE mRNA, a genetically validated target that could enable healthy weight loss by promoting fat burning while preserving muscle mass.
This innovative treatment approach has the potential for once- or twice-yearly dosing and could significantly address the global obesity epidemic, affecting over 1 billion people.
The INLIGHT trial will enroll adults with overweight or obesity to evaluate the safety, tolerability, pharmacokinetics, and efficacy of WVE-007.
Results are expected in 2025, with proof-of-concept clinical data focused on fat loss, muscle preservation, and improved metabolic health.
WVE-007 is Wave Life Sciences' first siRNA therapeutic to enter clinical development, marking a significant advancement in RNA interference technology and its application to common diseases like obesity.
Currently, WVE is trading at $12.23 down by 0.57%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.